Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 1, 2017

NICO receives new 510(k) clearance for technologies Myriad and BrainPath

NICO has received a new and updated 510(k) clearance from the US Food and Drug Administration (FDA) for two of its patented brain surgery technologies Myriad and BrainPath.

NICO has received a new and updated 510(k) clearance from the US Food and Drug Administration (FDA) for two of its patented brain surgery technologies Myriad and BrainPath.

Myriad it is an automated, multi-functional tool used for precise resection, suction, clot evacuation and tumour removal in neurosurgery, spinal surgery, ENT and otolaryngology.

Approximately 12,000 procedures have been already performed using this technology.

The FDA has updated the recently received clearance for Myriad automated tissue removal technology use in specific neurosurgical indications, to use in primary and secondary brain tumors, vascular abnormalities and malformations, and intraventricular tumors and cysts.

NICO president and chief executive officer Jim Pearson said: "NICO has spent the last five years bringing together key technology elements to enable minimally invasive neurosurgery for subcortical tumours and clots.

"The goal of NICO has always been to create technology that could create less deficits and faster recoveries in brain surgery.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

"The clinical evidence shows this is possible, and we believe that is directly related to finding less disruptive ways to access the brain that were not possible before.

"Approximately 12,000 procedures have been already performed using this technology."

"And we believe it will revolutionise the intracranial neurosurgical market."

With initial clearance secured in July 2015, BrainPath access technology is now cleared for use in specific disease conditions such as high grade gliomas and Glioblastoma Multiforme, secondary metastatic tumours, as well as vascular abnormalities like intracerebral hemorrhage.

Myriad and BrainPath can be combined for non-invasive access, automated tumour removal and clot evacuation near critical structures along with collection and preservation of  removed tissue and clots.


Image: NICO Myriad. Photo: courtesy of NICO Corporation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU